The excellent spatial resolution and expanded functionality of the Vevo® system greatly facilitates hepatology researchers to visualize and assess function in the liver, gall bladder and pancreas.
High-spatial resolution up to 30 μm allows for excellent delineation of anatomy associated with hepatology research in 2D and 3D, such as the liver, gall bladder and pancreas. Various associated pathologies such as hepatitis B or C, pancreatitis, gall stone and liver and pancreatic cancer can cause abnormal tissue changes such as liver cirrhosis, growth of tumors and presence of calcification. All of these examples can be detected and quantified by the Vevo system and tracked longitudinally in the same animal when therapy is administered.
Quantification of organ perfusion: Blood flow in the liver, pancreas and other associated organs can be detected and quantified at all vascular sizes. Pulsed-wave Doppler can obtain detailed velocity profiles in veins and arteries. Color and Power Doppler can detect and quantify flow in the smaller vessels in the 100 μm and greater range. Contrast imaging with infusion of contrast agents can quantify flow down to the capillary level. Collectively these can provide a detailed hemodynamic assessment in the organs associated with hepatology.
Image-guided injection and biopsy: The integrated rail system and the image-guided needle injection system enables needle injections to, and biopsies from, the liver, pancreas and/or surrounding tissue without the need of a surgical abdominal incision reducing recovery time and increasing throughput in large cohort studies. Examples of material injected can be cancer cells, stem cells or therapeutic compounds.
Detection and quantification of biomarkers: Biomarker expressions can be detected and quantified using Target-ready Vevo MicroMarker® contrast agents. For example, VEGF-R2-coupled Vevo MicroMarker contrast agents can be used as an angiogenesis marker in hepatoma in the same animal as its own control in longitudinal studies.
Gene transfection and enhanced drug delivery: The SoniGene™ Gene & Drug Delivery System is a device used in conjunction with Vevo 2100 or Vevo 770 system along with injection of Vevo MicroMarker microbubbles. The SoniGene system sends a pulse that disrupts the microbubbles in the organ of interest. Within the process, sonoporation is induced. If gene products or drugs are mixed with the Vevo MicroMarker contrast agent infusions, enhanced gene transfection and drug delivery can be induced in the hepatic cells.
Commonly used terminology:
liver, gallbladder, lobe, portal, hepatic, hepatocarcinoma, portal vein, hepatic artery, hepatic vein